Skip to main content

. 1973 Mar;49(3):163–196.

Pulmonary tuberculosis: evolution of modern therapy.

PMCID: PMC1806933 PMID: 4572586

163

Images in this article

Fig. 1a
on p.169

Fig. 1b
on p.170

Fig. 2a
on p.172

Fig. 2b
on p.174

Fig. 2c
on p.175

Fig. 3
on p.176

Fig. 4
on p.178

Fig. 5
on p.180

Fig. 6a
on p.181

Fig. 6b
on p.182

Fig. 7a
on p.186

Fig. 7b
on p.187

Fig. 8a
on p.188

Fig. 8b
on p.190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

CHAVES A. D., DANGLER G., ABELES H., ROBINS A. B., WIDELOCK D. The prevalence of drug-resistant strains of Mycobacterium tuberculosis isolated from untreated patients in New York City during 1960. Am Rev Respir Dis. 1961 Nov;84:647–656. doi: 10.1164/arrd.1961.84.5P1.647. [DOI] [PubMed] [Google Scholar]
Churchill E. D., Klopstock R. LOBECTOMY FOR PULMONARY TUBERCULOSIS. Ann Surg. 1943 May;117(5):641–669. doi: 10.1097/00000658-194305000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
Corpe R. F., Blalock F. A. Retreatment of drug resistant tuberculosis at Battey State Hospital. Dis Chest. 1965 Sep;48(3):305–310. doi: 10.1378/chest.48.3.305. [DOI] [PubMed] [Google Scholar]
Donomae I., Yamamoto K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann N Y Acad Sci. 1966 Apr 20;135(2):849–881. doi: 10.1111/j.1749-6632.1966.tb45528.x. [DOI] [PubMed] [Google Scholar]
GRUNBERG E., SCHNITZER R. J. Studies on the activity of hydrazine derivatives of isonicotinic acid in the experimental tuberculosis of mice. Q Bull Sea View Hosp. 1952 Jan;13(1):3–11. [PubMed] [Google Scholar]
Gyselen A., Verbist L., Cosemans J., Lacquet L. M., Vandenbergh E. Rifampin and ethambutol in the retreatment of advanced pulmonary tuberculosis. Am Rev Respir Dis. 1968 Dec;98(6):933–941. doi: 10.1164/arrd.1968.98.6.933. [DOI] [PubMed] [Google Scholar]
Hobby G. L., Lenert T. F. The antimycobacterial activity of rifampin. Am Rev Respir Dis. 1968 Apr;97(4):713–714. doi: 10.1164/arrd.1968.97.4.713. [DOI] [PubMed] [Google Scholar]
MCDERMOTT W. Isonicotinic acid derivatives in tuberculosis treatment; history of the development of the drugs. Trans Annu Meet Natl Tuberc Assoc. 1952;48:421–424. [PubMed] [Google Scholar]
Maggi N., Pallanza R., Sensi P. New derivatives of rifamycin SV. Antimicrob Agents Chemother (Bethesda) 1965;5:765–769. [PubMed] [Google Scholar]
ROBITZEK E. H., SELIKOFF I. J. Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report. Am Rev Tuberc. 1952 Apr;65(4):402–428. doi: 10.1164/art.1952.65.4.402. [DOI] [PubMed] [Google Scholar]
Shenstone N. S., Janes R. M. EXPERIENCES IN PULMONARY LOBECTOMY. Can Med Assoc J. 1932 Aug;27(2):138–145. [PMC free article] [PubMed] [Google Scholar]
THOMAS J. P., BAUGHN C. O., WILKINSON R. G., SHEPHERD R. G. A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2'-(ethylenediimino)-di-l-butanol). Am Rev Respir Dis. 1961 Jun;83:891–893. doi: 10.1164/arrd.1961.83.6.891. [DOI] [PubMed] [Google Scholar]

ACTIONS

PDF (9.4 MB)

RESOURCES